Dowpharma Announces Multi-Product License Agreement with Merck & Co., Inc.

February 26, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

MIDLAND, MICH - February 22, 2007 -- Dowpharma today announced that Merck & Co., Inc. has entered into a multi-product commercial license agreement for Pfenex Expression Technology™, a Pseudomonas-based technology from Dowpharma.

Twitter
LinkedIn
Facebook
Email
Print

Alliances